Trade Analytics

This is the ARCHIVED section of the website. To visit the current content of the website please CLICK here


Go Back

Indian Immunologicals plans Rs 300 crore vaccine plant in Pondicherry

The Economic Times:  January, 2015

Hyderabad: Hyderabad headquartered vaccine manufacturer Indian Immunologicals Ltd ( IIL), part of the National Dairy Development Board, is setting up a new vaccine manufacturing facility in Pondicherry involving an investment of Rs 300 crore.

This is the fourth facility for Indian Immunologicals, which currently has two facilities in Hyderabad and one in Ooty.

Talking to reporters in Hyderabad on Friday, the NDDB chairman T. Nanda Kumar said the proposed new investment in Pondicherry was part of the union government's strategy to meet the anticipated doubling of demand for veterinary vaccines. The demand is estimated to reach 600 million doses over the next 3-4 years from around 300 million doses now.

He said a decision on whether to manufacture new vaccines at the proposed Pondicherry facility or expand the existing portfolio is yet to be taken. He said land for the vaccine production facility was already acquired and a decision on variety of vaccine will be taken in a year during which all other necessary approvals will be availed.

Nanda Kumar said NDDB was also looking at increasing the semen production to 100 million semen trays from around 60 million now using best breed animals aimed at maintaining bio-security and biodiversity with disease-free animals. The board proposes to invest around Rs 400 crore by 2017 on the project.

The NDDB chairman also said the country is estimated to see oversupply of milk at around 145 million tons during 2014-15 surpassing the demand of some 138 million tons. This, coupled with lower export demand from in China and Russia, would result in pressure on selling price of milk and milk products.